More than 1,500 people who have sought support from the vaccine damage payment scheme after being injured or bereaved as a ...

While the headline numbers don't inspire much confidence, Moderna is a stock that deserves a closer look. The company still ...

Merck shares trade at a significant discount to peers. The company faces challenges, but there are reasons to be bullish.

Concerns about the COVID-19 shots have increased after a report that drug maker Moderna failed to inform the U.S. government ...

including an extensive pipeline of therapeutics in clinical trials that could be the booster shot the stock needs to generate a rebound. It's been more than four years since Moderna rose to ...

including an extensive pipeline of therapeutics in clinical trials that could be the booster shot the stock needs to generate a rebound. Let's discuss the pros and cons of buying Moderna stock.

Jared Holz, Mizuho Healthcare Sector strategist, joins 'Closing Bell Overtime' to talk Moderna and Novo Nordisk.

researchers recommended that people who received it get a second booster dose with an mRNA vaccine such as Moderna and Pfizer. According to the published results, there were 129 coronavirus ...

Moderna has reported preliminary clinical ... and seems to offer improved protection. The booster shot – called mRNA-1273.211 – offered better and longer-lasting protection compared to the ...